Abstract 3431
Background
An increasing proportion of elderly patients (pts) are now being seen at cancer centres, with an increasing incidence of sarcoma. This has become a growing challenge for health care providers, because of the worse prognosis of these pts and our poor knowledge from trials, were they are underrepresented or excluded.
Methods
We performed a retrospective review of elderly pts with soft tissue and bone sarcomas treated between 2012 and 2017 at Regina Elena National Cancer Institute. Overall, 124 pts, median age of 77 (range 70-92), were evaluated for: surgery, radiotherapy (RT), medical treatment and related toxicities.
Results
The most common histological subtypes were: pleomorphic sarcoma (32%); liposarcoma (17%); leiomyosarcoma (13%); mixofibrosarcoma (9%); bone sarcoma (7%); and others (22%). A total of 107 pts had localized disease at diagnosis and 98 of them had surgical resection. 10 pts received adjuvant chemotherapy (CT) (8 Adriamicin (ADM), 1 Gemcitabine (Gem) and 1 Imatinib (IM)) and 35 pts adjuvant RT. 2 pts, unsuitable for surgery, were treated with RT, and 7 had best supportive care (BSC) (median age: 80, range: 73-85). Of the 17 metastatic pts, 13 were treated with palliative surgery. After surgery, 3 pts had RT and 3 had single agent CT (1 ADM, 1 Epirubicin (EPI) and 1 patient with GIST received IM followed by 2nd line Sunitinib). The remaining 3 pts had BSC due to age > 80 yr and PS 2. 10 non-metastatic pts had recurrent disease and were treated with 1st line CT (3 EPI, 1 Dacabarzine, 2 Gem, 1 Pazopanib, 1 ADM, 1 Docetaxel/Gem, 1 Bleomicine/Vinblastine). 6 received 2 lines of CT after progression (4 Trabectidin and 2 Gem). 13 of 21 pts treated with CT had no toxicities. The most common toxicities observed in 8 pts left were: haematological (37%); gastrointestinal (12%), and transaminitis (25%).
Conclusions
In our analysis, “fit” elderly pts were treated with the same medical treatments as non-elderly pts. Tolerability was fairly good, without discontinuation or hospitalization. Only 8% were treated with BSC, a relevant result considering the median age of our pts. Future studies designed for elderly pts and rare tumours, such as sarcomas, are needed to improve survival rates and quality of life of this poorly represented group of pts.
Clinical trial identification
Legal entity responsible for the study
Regina Elena Sarcoma Group.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4742 - Ki67 as an important predictor for Oncotype Dx Recurrence score risk groups in Early Breast cancer
Presenter: Fernando Namuche
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4697 - Genetic signatures always suggest undertreatment? Experience with PAM51
Presenter: Carolina Sales
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3158 - Significance of receptors expression, mitotic index and Ki67 in breast cancer patients with Nottingham Prognostic Index (NPI) poor prognosis score
Presenter: Mejri Nesrine
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3838 - Subgroup analyses of efficacy from a phase III study comparing SB3 (trastuzumab biosimilar) with reference trastuzumab in early breast cancer patients
Presenter: Javier Cortes Castan
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
715 - Autoimmunity and benefit from trastuzumab treatment in breast cancer: results from the HERA phase 3 trial
Presenter: Amir Sonnenblick
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2388 - Impact of hormone receptor status in HER2+ early breast cancer: a paradigm shift in the trastuzumab era
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3742 - Sefety profile of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: The french HERMIONE non-interventional prospective study
Presenter: jean-philippe Jacquin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3647 - Real-life data on the cardiac toxicity of adjuvant fixed-dose subcutaneous trastuzumab in HER2-positive breast cancer.
Presenter: Rita De Sanctis
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3837 - Comprehensive evaluation of the pharmacokinetic profiles of SB3 and reference trastuzumab
Presenter: Xavier Pivot
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
1692 - The impact of neoadjuvant dual HER2 targeting with Pertuzumab and Trastuzumab on pathological complete response (pCR) rates: Kent Oncology Centre (KOC) experience
Presenter: Samantha Forner
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract